Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul;35(7):3062-8.
doi: 10.1118/1.2938520.

Targeted radionuclide therapy

Lawrence E Williams  1 , Gerald L DeNardo, Ruby F Meredith
Affiliations

Targeted radionuclide therapy

Lawrence E Williams et al. Med Phys. 2008 Jul.

Abstract

Targeted radionuclide therapy (TRT) seeks molecular and functional targets within patient tumor sites. A number of agents have been constructed and labeled with beta, alpha, and Auger emitters. Radionuclide carriers spanning a broad range of sizes; e.g., antibodies, liposomes, and constructs such as nanoparticles have been used in these studies. Uptake, in percent-injected dose per gram of malignant tissue, is used to evaluate the specificity of the targeting vehicle. Lymphoma (B-cell) has been the primary clinical application. Extension to solid tumors will require raising the macroscopic absorbed dose by several-fold over values found in present technology. Methods that may effect such changes include multistep targeting, simultaneous chemotherapy, and external sequestration of the agent. Toxicity has primarily involved red marrow so that marrow replacement can also be used to enhance future TRT treatments. Correlation of toxicities and treatment efficiency has been limited by relatively poor absorbed dose estimates partly because of using standard (phantom) organ sizes. These associations will be improved in the future by obtaining patient-specific organ size and activity data with hybrid SPECT/CT and PET/CT scanners.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Anterior gamma camera image of a medullary thyroid cancer patient. Image obtained at 48 h post-IV injection of 5 mCi (185 MBq) of 111In-cT84.66 anti-CEA antibody. Multiple bone lesions are seen in the pelvis and both femurs. Part of the right lobe of liver appears superiorly (see Ref. 37).
See this image and copyright information in PMC

References

    1. Jacobs A. J., Fer M., Su F. M., Breitz H., Thompson J., Goodgold H., Cani J., Heap J., and Weiden P., “A phase I trial of rhenium-186-labeled monoclonal antibody administered intraperitoneally in ovarian carcinoma: Toxicity and clinical response,” Obstet. Gynecol. (N.Y., NY, U. S.) 82, 586–593 (1993). - PubMed
    1. Riva P., Arista A., Tison V., Sturiale C., Francheschi G., Spinelli A., Riva N., Casi M., Moscatelli G., and Frattarelli M., “Intralesional radioimmunotherapy of malignant gliomas: An effective treatment in recurrent tumors,” Cancer 73, 1076–1082 (1994). - PubMed
    1. Shapiro B., Sisson J. C., Wieland D. M., Mangner T. J., Zempel S. M., Mudgett E., Gross M. D., Carey J. E., Zasadny K. R., and Beierwaltes W. H., “Radiopharmaceutical therapy of malignant pheochromocytoma with 131I metaiodobenzylguanidine: Results from ten years of experience,” J. Nucl. Biol. Med. 35, 269–276 (1991). - PubMed
    1. Frilling A., Weber F., Cicinnati V., and Broelsch C., “Role of radiolabeled octreotide therapy in patients with metastatic neuroendocrine neoplasms,” Exp. Rev. Endocrinology Metabolism 2, 517–527 (2007). - PubMed
    1. DeNardo G. L., Natarajan A., Hok S., Perkins J., Cosman M., DeNardo S. J., Lightstone F. C., Mirick G. L., Miers L. A., and Balhorn R. L., “Pharmacokinetic characterization in xenografted mice of a series of first-generation mimics for HLA-DR antibody, Lym-1, as carrier molecules to image and treat lymphoma,” J. Nucl. Med. 48, 1338–1347 (2007). - PubMed

Publication types

MeSH terms

LinkOut - more resources